Concentra Group Holdings Parent (CON) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 3.3% year-over-year to $489.6 million, with Adjusted EBITDA up 2.7% to $101.6 million, driven by higher revenue per visit and stable workers' compensation volume.

• Net income for Q3 2024 was $45.8 million, with EPS of $0.37, both lower due to higher interest expense post-IPO recapitalization.

• Expanded to 705 locations, including 549 occupational health centers and 156 onsite clinics, serving a highly diversified employer base.

• Completed IPO in July 2024, raising over $499 million, and declared a $0.0625/share dividend payable in November.

• Advanced separation from Select Medical, hiring key leaders and progressing toward full independence by end of 2026.

Financial highlights

• Q3 2024 revenue: $489.6 million (+3.3% YoY); Adjusted EBITDA: $101.6 million (+2.7% YoY); Adjusted EBITDA margin: 20.7% (down from 20.9%).

• Net income: $45.8 million; EPS: $0.37; cash at quarter-end: $136.8 million; net leverage: 3.7x.

• Revenue per visit increased 3.9% year-over-year to $141.42, driven by higher reimbursement rates and favorable mix.

• Total visits declined 0.7% year-over-year; employer services visits down 2.6%, workers' compensation visits up 1.7%.

• Operating cash flow was $65.9 million in Q3; capex $15.1 million.

Outlook and guidance

• Full-year 2024 guidance: revenue ~$1.9 billion, Adjusted EBITDA $370–$375 million, capex $65–$70 million, net leverage 3.5–3.6x.

• Guidance includes impacts from recent hurricanes and cyber events; 2025 guidance to be provided early next year.

• Management expects continued organic growth through new center openings and strategic acquisitions, funded by operating cash flow and available credit.

• Current cash and revolving credit availability are sufficient for short- and long-term needs.

• Expect continued growth, with optimism for 2025 as labor market stabilizes and Florida rate increase takes effect.